Archive

« Older Entries

argenx to receive third preclinical milestone payment from collaboration with LEO Pharma - Milestone associated with CTA approval for ARGX-112 Thursday, April 12th, 2018
Breda, the Netherlands/Ghent, Belgium, April 12, 2018 - argenx (Euronext & Nasdaq: ARGX) a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment o [...]
Zealand and Roche Diabetes Care enter Phase 3 study collaboration for treatment of congenital hyperinsulinism with dasiglucagon Wednesday, April 11th, 2018
Zealand has entered a collaboration agreement with Roche Diabetes Care to use its Accu-Chek® Combo pump system in the Phase 3 trials with dasiglucagon for treatment of congenital hyperinsulinism (CHI). The [...]
argenx appoints Keith Woods as Chief Operating Officer Monday, April 9th, 2018
Breda, the Netherlands / Ghent, Belgium, April 9, 2018 - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatmen [...]
argenx announces orphan drug designation for ARGX-113 for the treatment of myasthenia gravis in Europe Monday, March 26th, 2018
Breda, the Netherlands / Ghent, Belgium, March 26, 2018 - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatme [...]
Merus and the Vall d’Hebron Institute of Oncology Announce Research Collaboration to Develop Innovative Bispecific Antibodies for Therapeutic Application... Tuesday, March 20th, 2018
UTRECHT, The Netherlands, March 20, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), and the Vall d’He [...]
Merus Announces Ono Pharmaceuticals Exercise of its Option for New Research and License Agreement to Generate Bispecific Antibody Targeting Autoimmune Dise... Wednesday, March 14th, 2018
UTRECHT, The Netherlands, March 14, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced tha [...]
Merus’ Intellectual Property Portfolio Expands with Two New Patents Tuesday, March 13th, 2018
Merus’ First U.S. Patent Covering MCLA-117 and Merus’ Spleen to Screen® Technology for Efficient Generation of Biclonics® Candidates   UTRECHT, The Netherlands, March 13, 2018 (GLOBE NEWSWIRE) -- Merus N. [...]
Merus Announces $55.8 Million Private Placement Offering of Common Stock Wednesday, February 14th, 2018
UTRECHT, The Netherlands, Feb. 14, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that [...]
LSP invests in Simplify Medical to bring the company’s innovative cervical disc to the US Market Monday, February 12th, 2018
Amsterdam, the Netherlands - 12 February 2018 - LSP announces its investment in Simplify Medical. The LSP Health Economics Fund 2 (LSP HEF 2) leads the second tranche of the company’s Series B financing of $23.5 mil [...]
Her Majesty Queen Máxima launches Oncode Institute, founded by LSP's Rudy Dekeyser and René Kuijten Wednesday, February 7th, 2018
Oncode Institute combines 600 of the very best oncology researchers with a highly qualified valorisation staff to ensure that breakthrough discoveries get to patients faster.    The origins of Oncode go back [...]

« Older Entries

2018
2017
2016
2015
2014
2013
2012
back to archive overview
Follow us

Archive

« Older Entries

argenx to receive third preclinical milestone payment from collaboration with LEO Pharma - Milestone associated with CTA approval for ARGX-112 Thursday, April 12th, 2018
Breda, the Netherlands/Ghent, Belgium, April 12, 2018 - argenx (Euronext & Nasdaq: ARGX) a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment o [...]
Zealand and Roche Diabetes Care enter Phase 3 study collaboration for treatment of congenital hyperinsulinism with dasiglucagon Wednesday, April 11th, 2018
Zealand has entered a collaboration agreement with Roche Diabetes Care to use its Accu-Chek® Combo pump system in the Phase 3 trials with dasiglucagon for treatment of congenital hyperinsulinism (CHI). The [...]
argenx appoints Keith Woods as Chief Operating Officer Monday, April 9th, 2018
Breda, the Netherlands / Ghent, Belgium, April 9, 2018 - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatmen [...]
argenx announces orphan drug designation for ARGX-113 for the treatment of myasthenia gravis in Europe Monday, March 26th, 2018
Breda, the Netherlands / Ghent, Belgium, March 26, 2018 - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatme [...]
Merus and the Vall d’Hebron Institute of Oncology Announce Research Collaboration to Develop Innovative Bispecific Antibodies for Therapeutic Applicati... Tuesday, March 20th, 2018
UTRECHT, The Netherlands, March 20, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), and the Vall d’He [...]
Merus Announces Ono Pharmaceuticals Exercise of its Option for New Research and License Agreement to Generate Bispecific Antibody Targeting Autoimmune Di... Wednesday, March 14th, 2018
UTRECHT, The Netherlands, March 14, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced tha [...]
Merus’ Intellectual Property Portfolio Expands with Two New Patents Tuesday, March 13th, 2018
Merus’ First U.S. Patent Covering MCLA-117 and Merus’ Spleen to Screen® Technology for Efficient Generation of Biclonics® Candidates   UTRECHT, The Netherlands, March 13, 2018 (GLOBE NEWSWIRE) -- Merus N. [...]
Merus Announces $55.8 Million Private Placement Offering of Common Stock Wednesday, February 14th, 2018
UTRECHT, The Netherlands, Feb. 14, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that [...]
LSP invests in Simplify Medical to bring the company’s innovative cervical disc to the US Market Monday, February 12th, 2018
Amsterdam, the Netherlands - 12 February 2018 - LSP announces its investment in Simplify Medical. The LSP Health Economics Fund 2 (LSP HEF 2) leads the second tranche of the company’s Series B financing of $23.5 mil [...]
Her Majesty Queen Máxima launches Oncode Institute, founded by LSP's Rudy Dekeyser and René Kuijten Wednesday, February 7th, 2018
Oncode Institute combines 600 of the very best oncology researchers with a highly qualified valorisation staff to ensure that breakthrough discoveries get to patients faster.    The origins of Oncode go back [...]

« Older Entries

2018
2017
2016
2015
2014
2013
2012
back to archive overview